Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.61 |
| ▸ | PDE4A | P27815 | 1/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.50 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | SUV39H2 | Q9H5I1 | 7/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30422333 | 1.00 | TAAR1 (0.61) | TAAR1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL29768359 | 0.89 | PDE4A (0.52) | TAAR1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL15053663 | 0.89 | PDE4A (0.52) | TAAR1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL19628279 | 0.88 | PDE4A (0.50) | TAAR1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL16068898 | 0.88 | TAAR1 (0.52) | TAAR1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL16156475 | 0.87 | PDE4A (0.62) | TAAR1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3396291 | 0.85 | PDE4A (0.57) | TAAR1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL13696483 | 0.84 | PDE4A (0.47) | TAAR1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL12694342 | 0.83 | TAAR1 (0.78) | TAAR1GAANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL6739489 | 0.82 | TAAR1 (0.51) | TAAR1PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11666577-B2 | MLKL inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2023-06-06 | — | — | US | disclosed |
| CN-110573509-B | MLKL inhibitors | 北京生命科学研究所 | 2023-05-26 | — | — | CN | disclosed |
| CN-110573509-A | MLKL inhibitors | 北京生命科学研究所 | 2019-12-13 | — | — | CN | disclosed |
| US-9169182-B2 | Chrysophaentin analogs that inhibit FtsZ protein | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-10-27 | — | — | US | disclosed |
| US-9169182-B2 | Chrysophaentin analogs that inhibit FtsZ protein | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-10-27 | — | — | US | disclosed |
| US-9169182-B2 | Chrysophaentin analogs that inhibit FtsZ protein | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-10-27 | — | — | US | disclosed |
| CN-103649028-A | Clinostatin analogs that inhibit FtsZ proteins | US GOVERNMENT | 2014-03-19 | — | — | CN | disclosed |
| EP-2678297-A2 | CHRYSOPHAENTIN ANALOGS THAT INHIBIT FTSZ PROTEIN | The U.S.A. as represented by the Secretary, Department of Health and Human Services (US) | 2014-01-01 | — | — | EP | disclosed |
| US-20130331460-A1 | CHRYSOPHAENTIN ANALOGS THAT INHIBIT FTSZ PROTEIN | UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2013-12-12 | — | — | US | disclosed |
| US-20130331460-A1 | CHRYSOPHAENTIN ANALOGS THAT INHIBIT FTSZ PROTEIN | UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2013-12-12 | — | — | US | disclosed |
| US-20130331460-A1 | CHRYSOPHAENTIN ANALOGS THAT INHIBIT FTSZ PROTEIN | UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2013-12-12 | — | — | US | disclosed |
| WO-2012116254-A2 | CHRYSOPHAENTIN ANALOGS THAT INHIBIT FTSZ PROTEIN | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-08-30 | — | — | WO | disclosed |
| WO-2012116254-A2 | CHRYSOPHAENTIN ANALOGS THAT INHIBIT FTSZ PROTEIN | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11666577-B2 | MLKL inhibitors | MLKL, CMKLR1, PCSK9 | TAAR1 4879/4885PDE4A 2095/4885PDE4B 1621/4885 |
| US-20130331460-A1 | CHRYSOPHAENTIN ANALOGS THAT INHIBIT FTSZ PROTEIN | CDC42, CEP170, FNTA | TAAR1 4818/4885PDE4A 4334/4885PDE4B 4510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.